Search results
- Regulatory news (469) Apply Regulatory news filter
- Press releases (231) Apply Press releases filter
- Basic page (60) Apply Basic page filter
- Corporate presentations (26) Apply Corporate presentations filter
- Pipeline (26) Apply Pipeline filter
- Shareholder meeting (24) Apply Shareholder meeting filter
- Team member (22) Apply Team member filter
- Videos (16) Apply Videos filter
- Financial reports (12) Apply Financial reports filter
- Webcasts and audio (12) Apply Webcasts and audio filter
- Analyst (11) Apply Analyst filter
- Investor contact (6) Apply Investor contact filter
- Event (4) Apply Event filter
- Research (3) Apply Research filter
- Financial calendar (1) Apply Financial calendar filter
- Webform (1) Apply Webform filter
Oxford BioMedica notes the sBLA submission to FDA for Kymriah™ in adult patients with r/r DLBCL
Oxford, UK – 31 October 2017: Oxford BioMedica plc (“Oxford BioMedica” or “the Group”) (LSE:OXB), a leading gene and cell therapy